Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Drug development against human adenoviruses and its advancement by Syrian hamster models.

Wold WSM, Tollefson AE, Ying B, Spencer JF, Toth K.

FEMS Microbiol Rev. 2019 Jul 1;43(4):380-388. doi: 10.1093/femsre/fuz008. Review.

PMID:
30916746
2.

Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9.

Miao J, Ying B, Li R, Tollefson AE, Spencer JF, Wold WSM, Song SH, Kong IK, Toth K, Wang Y, Wang Z.

Viruses. 2018 May 6;10(5). pii: E243. doi: 10.3390/v10050243.

3.

USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses.

Toth K, Spencer JF, Ying B, Tollefson AE, Hartline CB, Richard ET, Fan J, Lyu J, Kashemirov BA, Harteg C, Reyna D, Lipka E, Prichard MN, McKenna CE, Wold WSM.

Antiviral Res. 2018 May;153:1-9. doi: 10.1016/j.antiviral.2018.03.001. Epub 2018 Mar 3.

4.

Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females.

Ying B, Spencer JF, Tollefson AE, Wold WSM, Toth K.

Virology. 2018 Jan 15;514:66-78. doi: 10.1016/j.virol.2017.10.015. Epub 2017 Nov 10.

5.

Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters.

Schaar K, Geisler A, Kraus M, Pinkert S, Pryshliak M, Spencer JF, Tollefson AE, Ying B, Kurreck J, Wold WS, Klopfleisch R, Toth K, Fechner H.

Mol Ther Nucleic Acids. 2017 Sep 15;8:300-316. doi: 10.1016/j.omtn.2017.07.002. Epub 2017 Jul 8.

6.

Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds.

Toth K, Tollefson AE, Spencer JF, Ying B, Wold WSM.

Antiviral Res. 2017 Oct;146:121-129. doi: 10.1016/j.antiviral.2017.08.002. Epub 2017 Aug 4.

PMID:
28827083
7.

HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.

Toth K, Spencer JF, Ying B, Tollefson AE, Wold WSM.

Viruses. 2017 Jun 13;9(6). pii: E147. doi: 10.3390/v9060147.

8.

Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Tollefson AE, Ying B, Spencer JF, Sagartz JE, Wold WSM, Toth K.

J Virol. 2017 Apr 28;91(10). pii: e00284-17. doi: 10.1128/JVI.00284-17. Print 2017 May 15.

9.

Correction: STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control.

Toth K, Lee SR, Ying B, Spencer JF, Tollefson AE, Sagartz JE, Kong IK, Wang Z, Wold WS.

PLoS Pathog. 2016 Jan 8;12(1):e1005392. doi: 10.1371/journal.ppat.1005392. eCollection 2016 Jan.

10.

STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control.

Toth K, Lee SR, Ying B, Spencer JF, Tollefson AE, Sagartz JE, Kong IK, Wang Z, Wold WS.

PLoS Pathog. 2015 Aug 20;11(8):e1005084. doi: 10.1371/journal.ppat.1005084. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2016 Jan;12(1):e1005392.

11.

Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters.

Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, Buller RM, Wold WS.

Viruses. 2015 Mar 23;7(3):1409-28. doi: 10.3390/v7031409.

12.

Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.

Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K.

Antiviral Res. 2014 Dec;112:38-46. doi: 10.1016/j.antiviral.2014.10.005. Epub 2014 Oct 15.

PMID:
25453340
13.

Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication.

Tavis JE, Wang H, Tollefson AE, Ying B, Korom M, Cheng X, Cao F, Davis KL, Wold WS, Morrison LA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7451-61. doi: 10.1128/AAC.03875-14. Epub 2014 Sep 29.

14.

Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.

Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, Buller RM, Toth K, Wold WS.

Antimicrob Agents Chemother. 2014 Dec;58(12):7171-81. doi: 10.1128/AAC.03860-14. Epub 2014 Sep 15.

15.

Adenovirus death protein (ADP) is required for lytic infection of human lymphocytes.

Murali VK, Ornelles DA, Gooding LR, Wilms HT, Huang W, Tollefson AE, Wold WS, Garnett-Benson C.

J Virol. 2014 Jan;88(2):903-12. doi: 10.1128/JVI.01675-13. Epub 2013 Nov 6.

16.

The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.

Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS.

Cancer Gene Ther. 2013 Sep;20(9):521-30. doi: 10.1038/cgt.2013.49. Epub 2013 Aug 9.

17.

Identification of a previously unrecognized promoter that drives expression of the UXP transcription unit in the human adenovirus type 5 genome.

Ying B, Tollefson AE, Wold WS.

J Virol. 2010 Nov;84(21):11470-8. doi: 10.1128/JVI.01338-10. Epub 2010 Aug 25.

18.

An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.

Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WS, Toth K.

Cancer Gene Ther. 2009 Aug;16(8):644-54. doi: 10.1038/cgt.2009.5. Epub 2009 Feb 6.

19.

INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL.

Cancer Gene Ther. 2009 Aug;16(8):625-37. doi: 10.1038/cgt.2009.6. Epub 2009 Feb 6.

20.

Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit.

Tollefson AE, Ying B, Doronin K, Sidor PD, Wold WS.

J Virol. 2007 Dec;81(23):12918-26. Epub 2007 Sep 19.

21.

Preparation and titration of CsCl-banded adenovirus stocks.

Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS.

Methods Mol Med. 2007;130:223-35.

PMID:
17401177
22.

Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.

Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS.

Cancer Res. 2006 Feb 1;66(3):1270-6.

23.

Ceramide regulates SR protein phosphorylation during adenoviral infection.

Kanj SS, Dandashi N, El-Hed A, Harik H, Maalouf M, Kozhaya L, Mousallem T, Tollefson AE, Wold WS, Chalfant CE, Dbaibo GS.

Virology. 2006 Feb 5;345(1):280-9. Epub 2005 Nov 3.

24.

Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.

Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.

Gene Ther. 2005 Nov;12(22):1608-17.

PMID:
16034456
25.

Cotton rat tumor model for the evaluation of oncolytic adenoviruses.

Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL, La Regina MC, Prince GA, Wold WS.

Hum Gene Ther. 2005 Jan;16(1):139-46.

PMID:
15703497
26.

Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice.

Toth K, Doronin K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS.

Virus Res. 2005 Mar;108(1-2):149-59.

PMID:
15681065
27.

Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Lichtenstein DL, Doronin K, Toth K, Kuppuswamy M, Wold WS, Tollefson AE.

J Virol. 2004 Nov;78(22):12297-307.

28.

An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling.

Toth K, Djeha H, Ying B, Tollefson AE, Kuppuswamy M, Doronin K, Krajcsi P, Lipinski K, Wrighton CJ, Wold WS.

Cancer Res. 2004 May 15;64(10):3638-44.

29.

Functions and mechanisms of action of the adenovirus E3 proteins.

Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS.

Int Rev Immunol. 2004 Jan-Apr;23(1-2):75-111. Review.

PMID:
14690856
30.
32.

A multitasking oncolytic adenovirus vector.

Toth K, Doronin K, Tollefson AE, Wold WS.

Mol Ther. 2003 Apr;7(4):435-7. No abstract available.

33.

Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus.

Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS.

Virology. 2003 Jan 20;305(2):378-87.

34.
35.

Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain.

Kladney RD, Tollefson AE, Wold WS, Fimmel CJ.

Virology. 2002 Sep 30;301(2):236-46.

36.

Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc).

Habib NA, Mitry R, Seth P, Kuppuswamy M, Doronin K, Toth K, Krajcsi P, Tollefson AE, Wold WS.

Cancer Gene Ther. 2002 Aug;9(8):651-4.

37.

Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.

Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, Hermiston TW, Smith CA, Wold WS.

J Virol. 2001 Oct;75(19):8875-87.

38.

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.

Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V, Wold WS.

J Virol. 2001 Apr;75(7):3314-24.

39.

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.

Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS.

J Virol. 2000 Jul;74(13):6147-55.

40.

GP73, a novel Golgi-localized protein upregulated by viral infection.

Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ.

Gene. 2000 May 16;249(1-2):53-65.

PMID:
10831838
41.

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE.

Curr Opin Immunol. 1999 Aug;11(4):380-6. Review.

PMID:
10448144
42.

Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells.

Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WS.

Nature. 1998 Apr 16;392(6677):726-30.

PMID:
9565035
43.

Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.

Dimitrov T, Krajcsi P, Hermiston TW, Tollefson AE, Hannink M, Wold WS.

J Virol. 1997 Apr;71(4):2830-7.

44.
45.
46.
48.

E3 transcription unit of adenovirus.

Wold WS, Tollefson AE, Hermiston TW.

Curr Top Microbiol Immunol. 1995;199 ( Pt 1):237-74. Review. No abstract available.

PMID:
7555057
49.

Adenovirus proteins that subvert host defenses.

Wold WS, Hermiston TW, Tollefson AE.

Trends Microbiol. 1994 Nov;2(11):437-43. Review.

PMID:
7532531
50.

Supplemental Content

Loading ...
Support Center